Highlights
• ACA-DK rescues HFD-induced dyslipidemia by counteracting weight gain and aberrant lipid profiles.
• Dual metabolic reprogramming: ACA-DK remodels glycerophospholipid, choline, and linoleic acid pathways to modulate hepatic TG/PC/PE.
• Targeted microbial suppression: ACA-DK selectively reduces pro-inflammatory Ruminococcaceae (e.g., Oscillibacter, Ruminiclostridium) and Helicobacter.
• Ruminococcaceae identified as therapeutic target for lipid disorders via microbiota-host metabolic crosstalk.

京公网安备11010802044758号
Comments on this article